Julie Mori, PhD

Principal Virologist
hVivo Services LTD
London, England, United Kingdom

Disclosure: hVIVO: Employee, Shareholder

Presentation(s):

• LB6 - EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study

  Thursday, October 3
  2:35 PM – 2:45 PM